379 related articles for article (PubMed ID: 22566409)
1. Effects of surfactants on the properties of PLGA nanoparticles.
Menon JU; Kona S; Wadajkar AS; Desai F; Vadla A; Nguyen KT
J Biomed Mater Res A; 2012 Aug; 100(8):1998-2005. PubMed ID: 22566409
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of teniposide PLGA nanoparticles and their uptake in human glioblastoma U87MG cells.
Mo L; Hou L; Guo D; Xiao X; Mao P; Yang X
Int J Pharm; 2012 Oct; 436(1-2):815-24. PubMed ID: 22846410
[TBL] [Abstract][Full Text] [Related]
4. Augmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal model.
Jain AK; Swarnakar NK; Das M; Godugu C; Singh RP; Rao PR; Jain S
Mol Pharm; 2011 Aug; 8(4):1140-51. PubMed ID: 21557558
[TBL] [Abstract][Full Text] [Related]
5. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model.
Shah N; Chaudhari K; Dantuluri P; Murthy RS; Das S
J Drug Target; 2009 Aug; 17(7):533-42. PubMed ID: 19530913
[TBL] [Abstract][Full Text] [Related]
7. Impact of surfactants on the target recognition of Fab-conjugated PLGA nanoparticles.
Kennedy PJ; Perreira I; Ferreira D; Nestor M; Oliveira C; Granja PL; Sarmento B
Eur J Pharm Biopharm; 2018 Jun; 127():366-370. PubMed ID: 29549023
[TBL] [Abstract][Full Text] [Related]
8. Preparation and characterization novel polymer-coated magnetic nanoparticles as carriers for doxorubicin.
Li F; Sun J; Zhu H; Wen X; Lin C; Shi D
Colloids Surf B Biointerfaces; 2011 Nov; 88(1):58-62. PubMed ID: 21764271
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
Sun B; Ranganathan B; Feng SS
Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
[TBL] [Abstract][Full Text] [Related]
10. Chitosan-coated PLGA nanoparticles: a sustained drug release strategy for cell cultures.
Chronopoulou L; Massimi M; Giardi MF; Cametti C; Devirgiliis LC; Dentini M; Palocci C
Colloids Surf B Biointerfaces; 2013 Mar; 103():310-7. PubMed ID: 23261553
[TBL] [Abstract][Full Text] [Related]
11. Improved delivery of the natural anticancer drug tetrandrine.
Shi C; Ahmad Khan S; Wang K; Schneider M
Int J Pharm; 2015 Feb; 479(1):41-51. PubMed ID: 25510598
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells.
Wang H; Agarwal P; Zhao S; Xu RX; Yu J; Lu X; He X
Biomaterials; 2015 Dec; 72():74-89. PubMed ID: 26344365
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells.
Grabowski N; Hillaireau H; Vergnaud J; Santiago LA; Kerdine-Romer S; Pallardy M; Tsapis N; Fattal E
Int J Pharm; 2013 Oct; 454(2):686-94. PubMed ID: 23747506
[TBL] [Abstract][Full Text] [Related]
14. Development of poly(lactic-co-glycolic) acid nanoparticles-embedded hyaluronic acid-ceramide-based nanostructure for tumor-targeted drug delivery.
Park JH; Lee JY; Termsarasab U; Yoon IS; Ko SH; Shim JS; Cho HJ; Kim DD
Int J Pharm; 2014 Oct; 473(1-2):426-33. PubMed ID: 25079433
[TBL] [Abstract][Full Text] [Related]
15. Ultrafine PEG-coated poly(lactic-co-glycolic acid) nanoparticles formulated by hydrophobic surfactant-assisted one-pot synthesis for biomedical applications.
Chu CH; Wang YC; Huang HY; Wu LC; Yang CS
Nanotechnology; 2011 May; 22(18):185601. PubMed ID: 21415469
[TBL] [Abstract][Full Text] [Related]
16. Real-time visualization of pH-responsive PLGA hollow particles containing a gas-generating agent targeted for acidic organelles for overcoming multi-drug resistance.
Ke CJ; Chiang WL; Liao ZX; Chen HL; Lai PS; Sun JS; Sung HW
Biomaterials; 2013 Jan; 34(1):1-10. PubMed ID: 23044041
[TBL] [Abstract][Full Text] [Related]
17. PLGA/polymeric liposome for targeted drug and gene co-delivery.
Wang H; Zhao P; Su W; Wang S; Liao Z; Niu R; Chang J
Biomaterials; 2010 Nov; 31(33):8741-8. PubMed ID: 20727587
[TBL] [Abstract][Full Text] [Related]
18. AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery.
Aravind A; Jeyamohan P; Nair R; Veeranarayanan S; Nagaoka Y; Yoshida Y; Maekawa T; Kumar DS
Biotechnol Bioeng; 2012 Nov; 109(11):2920-31. PubMed ID: 22615073
[TBL] [Abstract][Full Text] [Related]
19. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
[TBL] [Abstract][Full Text] [Related]
20. Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
Laquintana V; Denora N; Lopalco A; Lopedota A; Cutrignelli A; Lasorsa FM; Agostino G; Franco M
Mol Pharm; 2014 Mar; 11(3):859-71. PubMed ID: 24410438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
